Significant advances have taken place in the management of patients with advanced and metastatic non–small-cell lung cancer (NSCLC) over the last 5 years. Traditionally, all advanced NSCLC patients ...

When Jeanne Szurek, 69, was diagnosed with stage IV epidermal growth factor receptor (EGFR)-positive lung cancer in 2024, she wondered if her two adult children were at a higher risk of developing the ...

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) guidelines all ...

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...

Diagnosis requires a tissue biopsy for histopathologic and immunohistochemistry evaluation. Testing for alterations using non-small cell lung cancer (NSCLC) tumor tissue requires acquisition of a ...

This systematic review and network meta-analysis evaluates first-line treatment options for patients with EGFR-mutant non-small cell lung cancer (NSCLC) and brain metastases. We analyzed 24 randomized ...

The biomarker development pipeline is presented in Fig. 1A. EGFR-RPV was developed using multi-regional segmentation, comprehensive radiomic feature extraction in a multi-regional approach (regions of ...

Feasibility of induction chemoimmunotherapy (ID chemo-IO) followed by chemoradiation for locally advanced unresectable non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the ...

A year after guidelines were revised to remove the use of race in eGFR, many labs and pathologists were still relying on the dangerously outdated version of the test. In recent years, the medical ...